Monte Rosa Therapeutics (GLUE) Free Cash Flow (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Free Cash Flow of -$40.1 million for Q1 2026, up 12.43% year-over-year from -$35.7 million in Q1 2025, and up 6.13% quarter-over-quarter from -$42.7 million in Q4 2025.
Monte Rosa Therapeutics (GLUE) Free Cash Flow (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$40.1 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 12.43% year-over-year to -$40.1 million; the TTM figure through Mar 2026 stood at -$17.3 million (down 148.89% YoY), while the FY2025 annual figure was -$22.9 million, down 154.71% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$40.1 million, up from -$42.7 million in the prior quarter.
- The five-year high for Free Cash Flow was $132.7 million in Q4 2024, with the low at -$45.8 million in Q1 2025.
- The 5-year median for Free Cash Flow is -$30.2 million (2024), against an average of -$11.1 million.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow tumbled 148.64% in 2022, then soared 1018.41% in 2024.
- Monte Rosa Therapeutics' Free Cash Flow stood at -$32.1 million in 2022, then surged by 136.93% to $11.9 million in 2023, then jumped by 1018.41% to $132.7 million in 2024, then slumped by 132.2% to -$42.7 million in 2025, then climbed by 6.13% to -$40.1 million in 2026.
- Business Quant data shows GLUE's Free Cash Flow at -$40.1 million in Q1 2026, -$42.7 million in Q4 2025, and $103.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - | -47.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -47.97 Mn |
| Jun 30, 2026 | -47.97 Mn |
| Mar 31, 2026 | -40.11 Mn |
| Mar 31, 2026 | -40.11 Mn |
| Dec 31, 2025 | -42.72 Mn |
| Dec 31, 2025 | -42.72 Mn |
| Sep 30, 2025 | 103.27 Mn |
| Sep 30, 2025 | 103.27 Mn |
| Jun 30, 2025 | -37.70 Mn |
| Jun 30, 2025 | -37.70 Mn |
| Mar 31, 2025 | -45.80 Mn |
| Mar 31, 2025 | -45.80 Mn |
| Dec 31, 2024 | 132.68 Mn |
| Dec 31, 2024 | 132.68 Mn |
| Sep 30, 2024 | -21.39 Mn |
| Sep 30, 2024 | -21.39 Mn |
| Jun 30, 2024 | -30.19 Mn |
| Jun 30, 2024 | -30.19 Mn |
| Mar 31, 2024 | -39.15 Mn |
| Mar 31, 2024 | -39.15 Mn |